Abstract
For patients able to have surgery for pancreatic cancer, the adjuvant use of gemcitabine plus capecitabine, instead of gemcitabine alone, leads to a significant improvement in 5-year survival, according to results of the ESPAC-4 trial. The finding will likely change the standard of care for these patients.
©2016 American Association for Cancer Research.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Capecitabine / therapeutic use*
-
Chemotherapy, Adjuvant
-
Clinical Trials, Phase III as Topic
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Gemcitabine
-
Humans
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / surgery
-
Randomized Controlled Trials as Topic
-
Survival Analysis
-
Treatment Outcome
Substances
-
Deoxycytidine
-
Capecitabine
-
Gemcitabine